Myovant Sciences is a biopharmaceutical company developing innovative treatment solutions for women's health conditions and endocrine-related disorders.
Myovant Sciences developed Relugolix, a once-daily oral medication developed to reduce testosterone production in men with prostate cancer, as testosterone enables and promotes prostate cancer growth. Relugolix is also believed to be effective in women experiencing Endometriosis and uterine fibroids, other testosterone-driven ailments.
The FDA has approved a priority review of Relugolix for the indication of prostate cancer treatment, however, will not yet be reviewing the effectiveness in women.
Myovant is presently developing an additional pharmaceutical therapy called MVT-602, this medication is intended to trigger egg maturation in women undergoing fertility treatments, including IVF (in vitro fertilization). This treatment is moving towards phase three before submission to the FDA for approval.
Myovant Sciences is a publically traded company with the ticker (MYOV) and can be traded on the NYSE and NASDAQ markets.
On August 5, 2020 Myovant announced $200 Million in Post-IPO Debt funding from Dainippon Sumitomo Pharma, a Japanese pharmaceutical company.